Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
← catalyst calendarNCT06881784 · readout in 469 d
Sponsored by Revolution Medicines, Inc. (industry) · RVMD — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
590estimated
Sites
152
Countries
Australia, Belgium, France +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-06 | actual | When the study began enrolling |
| Primary completion | 2027-12-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- NSCLC (Non-small Cell Lung Cancer)
- Non-Small Cell Lung Cancer
- NSCLC
- NSCLC (Non-small Cell Lung Carcinoma)
- NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
- Drug: daraxonrasib
- Drug: docetaxel
Primary outcomes
what the primary-completion date above is the date OFProgression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)
measured Up to approximately 4 years
Overall survival (OS) in the RAS G12X-C population
measured Up to approximately 4 years
Permalink · RVMD's whole pipeline · Catalyst calendar · Every registered study · What changed